DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Total Current Assets
All assets expected to be converted to cash or used up within one year.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 39.9% from a year ago
Total current assets stood at $52.36M at the end of Q1 FY2026, up 39.9% from a year earlier and down 13.6% from the prior quarter. Over 3 fiscal years it compounded at +21.5% a year.
Context
- Total current assets amounted to 98.6% of total assets at the end of Q1 FY2026, up 2.3 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +39.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 60.63M USD
- Year-over-year change
- +35.9%
- 4-year CAGR
- +7.5%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60.63M | +35.9% |
| FY2024 | 2024-12-31 | 44.61M | -16.9% |
| FY2023 | 2023-12-31 | 53.68M | +58.6% |
| FY2022 | 2022-12-31 | 33.84M | -25.5% |
| FY2021 | 2021-12-31 | 45.44M | — |
Total Current Assets vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 total current assets of $52.36M is the lowest of the 7 companies compared; the peer median is $311.63M.
- Its year-over-year change of +39.9% is the 2nd highest of 7, against a peer median of +20.1%.
- Total current assets amounts to 98.6% of total assets for DMAC, versus a peer median of 85.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $753.93M | -19.3% | -13.1% | 65.1% | |
BIOABioAge Labs, Inc. | Mar 2026 | $391.86M | +20.6% | +117.1% | 98.5% |
| Mar 2026 | $379.78M | +26.7% | +48.8% | 90.5% | |
| Mar 2026 | $243.48M | +19.5% | -0.1% | 67.2% | |
| Mar 2026 | $234.9M | -34.7% | -17.8% | 80.2% | |
| Mar 2026 | $63.55M | +132.4% | +164.6% | 98.7% | |
| Mar 2026 | $52.36M | +39.9% | +21.5% | 98.6% | |
| Peer median (excluding DMAC) | $311.63M | +20.1% | +24.4% | 85.4% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.